ArticleFuture oncology (London, England)2025
Clinical outcomes of everolimus in patients with hormone receptor positive breast cancer: a real-world analysis.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe study aimed to evaluate the effectiveness and safety of everolimus combined with endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.
methodsData from adult patients with HR+/HER2- advanced breast cancer at Beijing Cancer Hospital between January 2012 and February 2025 were analyzed retrospectively.
resultsA total of 137 patients were included and the median progression-free survival (PFS) was 4.13 months (95% confidence interval [CI]: 2.86-5.40). The objective response rate and disease control rate (DCR) were 10.9% and 51.1%, respectively. No significant difference was found in PFS between different lines of therapy (p = 0.433) or different combination drugs with everolimus (p = 0.528). The median PFS in patients without prior use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors was 4.20 months, compared to 3.07 months in patients previously treated with CDK4/6 inhibitors (p = 0.466). The patients with prior CDK4/6 inhibitors for more than six months exhibited an extended PFS when subsequently treated with everolimus plus endocrine therapy (7.63 vs. 2.03 months, p<0.001). Meanwhile, everolimus-based treatment was generally well-tolerated.
conclusionFor patients with HR+/HER2- advanced breast cancer, everolimus combined with endocrine therapy may serve as an alternative option after disease progression on CDK4/6 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.